Argus Upgrades Novartis to Buy With $180 Price Target

Group 1 - Novartis was upgraded to Buy from Hold by Argus, with a price target set at $180, indicating a long-term pattern of higher highs and higher lows for the stock [1] - The stock's 14-day relative strength index dropped to 56, presenting an attractive entry point for healthcare investors following a recent pullback [1] - Novartis experienced strong demand across its portfolio, with product volumes increasing by 18% during the fourth quarter [2] Group 2 - The company's dividend was recently increased by 5.7% after shareholder approval, resulting in a yield of approximately 3.0%, which is considered an attractive component of the investment case [2] - The $180 price target implies a potential total return of roughly 15% from current levels when including dividend income [3]